MOUNTAIN VIEW, Calif., Oct. 18, 2016 /PRNewswire-iReach/ -- Specific Technologies today announced it has appointed Rob Lozuk as company President. "Rob has a proven track record of bringing new technologies to commercial success and driving operational excellence. Rob is a dynamic leader and healthcare industry veteran with significant experience in go-to-market, sales and operations and deep knowledge of our markets. I am delighted that he will join us as President" said Paul Rhodes CEO. "I have tremendous confidence in Rob's ability to drive the commercialization of Specific Technologies transformative solution for identification of microorganisms in blood causing sepsis." continued Rhodes.
Prior to joining the company, Mr. Lozuk served as Senior Vice President, Commercial Operations of Sequenom from 2012 to 2016, overseeing the commercial organization that enabled Sequenom's recent $371M sale to LabCorp. Previously, Mr. Lozuk spent several years as an executive of Thermo Fisher, with roles including Director of Business Development, Director of Advanced Staining Operations, and Director of Business Development and Americas Marketing.
As President Mr. Lozuk will lead the company's development, marketing and operational organizations. "It is truly an honor to be appointed President of Specific Technologies. Specific's novel rapid, low cost technology for simultaneous detection and identification of microorganisms is game changing. I am looking forward to assuming a leadership role as the company brings the first of its transformative products to clinical microbiology." said Lozuk.
"By combining rapid detection, gram classification and species identification of bloodstream infections we will provide unrivaled speed while collapsing previously separate, often labor intensive or costly steps, into one entirely hands free instrument. Our customers require this cost effective diagnostic performance and we are well positioned to meet their needs."
"This is a coup for our organization and an important talent milestone as we move forward with the commercialization of our products. Rob is natural leader, customer focused, and brings us critical healthcare domain experience" said Ray Martino COO. "Adding a healthcare veteran leader of this caliber is major step toward realizing our company vision."
About the SpecID System
During growth in culture, bacteria produce small molecule volatile metabolites unique to their species and strain. Utilizing an inexpensive printed chemical sensor array to obtain a fingerprint that combines detection and identification into a simple, automated single step, the novel SpecID system identifies microorganism species and strain from a phenotypic metabolomic signature obtained during growth. The fully automated system will streamline lab work flow, reduce costs, and substantially shorten the time from sample arrival to the Gram status and species ID determination, truly lowering costs while improving patient care by speeding sample-to-answer in blood culture and soon other clinically important samples.
About the SpecID System
Specific Technologies has developed in vitro diagnostic systems for rapid identification of cells at the strain level, and is applying this fundamental new platform to the detection and characterization of microorganisms during culture. The company's unique, patented metabolomic signature technology leverages a low-cost printed chemical colorimetric sensor array to identify cell type down to the strain level. Specific Technologies is located in Mountain View, CA.
Media Contact: Press Contact, Specific Technologies, 650 938 6200, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Specific Technologies